Insulet (PODD) Total Non-Current Liabilities (2010 - 2026)
Insulet (PODD) posted Total Non-Current Liabilities of $1.6 billion for Q1 2026, little changed on a QoQ basis from $1.6 billion in Q4 2025, and down 24.19% year-over-year from $2.1 billion in Q1 2025.
Insulet (PODD) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Insulet's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $1.6 billion for Q1 2026.
- Quarterly Total Non-Current Liabilities fell 24.19% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 24.19% YoY) and the FY2025 annual result came in at $1.6 billion, down 11.71% from the prior year.
- Total Non-Current Liabilities was $1.6 billion for Q1 2026 at Insulet, roughly flat from $1.6 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.1 billion in Q1 2025 and bottomed at $1.6 billion in Q3 2025.
- A 5-year average of $1.8 billion and a median of $1.8 billion in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities rose 29.78% — and 2026, when it declined 24.19%.
- Insulet's Total Non-Current Liabilities stood at $1.7 billion in 2022, then gained by 4.52% to $1.8 billion in 2023, then climbed by 0.37% to $1.8 billion in 2024, then retreated by 11.71% to $1.6 billion in 2025, then gained by 0.38% to $1.6 billion in 2026.
- Business Quant data shows PODD's Total Non-Current Liabilities at $1.6 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 41.44 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 41.88 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 2.64 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 3.53 Bn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 24.21 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | 3.57 Bn |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 9.85 Bn |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | 1.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.62 Bn |
| Dec 31, 2025 | 1.61 Bn |
| Sep 30, 2025 | 1.58 Bn |
| Jun 30, 2025 | 1.95 Bn |
| Mar 31, 2025 | 2.13 Bn |
| Dec 31, 2024 | 1.82 Bn |
| Sep 30, 2024 | 1.86 Bn |
| Jun 30, 2024 | 1.85 Bn |
| Mar 31, 2024 | 1.80 Bn |
| Dec 31, 2023 | 1.82 Bn |
| Sep 30, 2023 | 1.82 Bn |
| Jun 30, 2023 | 1.79 Bn |
| Mar 31, 2023 | 1.75 Bn |
| Dec 31, 2022 | 1.74 Bn |
| Sep 30, 2022 | 1.71 Bn |
| Jun 30, 2022 | 1.66 Bn |
| Mar 31, 2022 | 1.61 Bn |
| Dec 31, 2021 | 1.48 Bn |
| Sep 30, 2021 | 1.49 Bn |
| Jun 30, 2021 | 1.45 Bn |